GlucoSentient
Private Company
Funding information not available
Overview
GlucoSentient is a privately-held, pre-revenue biotech company developing a novel diagnostic platform that transforms standard blood glucose meters into multi-analyte testing devices. Its core technology translates the presence of non-glucose targets—such as proteins, small molecules, and nucleic acids—into a glucose signal that can be read by any commercially available glucose meter. The company is targeting significant unmet needs in home-based therapeutic drug monitoring and chronic disease management, with initial grant-funded programs focused on monitoring transplant patients, phenylketonuria (PKU), and bipolar disorder. Backed by over $2 million in SBIR grants and led by a team with deep expertise in bioengineering and diagnostics, GlucoSentient aims to democratize access to frequent, quantitative biomarker testing.
Technology Platform
A patent-pending biochemical translation technology that repurposes standard blood glucose meters (BGMs) as universal readers. It converts the concentration of a non-glucose target (e.g., protein, drug, ion) into a proportional glucose signal, which is then quantified by the BGM.
Opportunities
Risk Factors
Competitive Landscape
Competition includes established point-of-care diagnostic companies (e.g., Abbott, Roche) with dedicated hardware systems and central lab services. New entrants are also exploring smartphone-based diagnostics and other connected home testing solutions. GlucoSentient's unique differentiator is its leverage of the familiar, FDA-cleared BGM hardware, potentially offering a lower-cost and more accessible alternative.